Literature DB >> 26926319

Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.

Stephen Brunton1, Jaime A Davidson2.   

Abstract

PURPOSE: The pathophysiology of type 2 diabetes mellitus is complex and involves multiple organs and hormones, suggesting that successful treatment may require therapies that target multiple mechanisms. Exenatide, a glucagon-like peptide 1 receptor agonist, has a multifaceted mechanism of action involving pancreatic α and β cells, hepatic glucose production, gastric motility, and satiety. Exenatide once weekly (a twice-daily formulation is also available) utilizes continuous release from biodegradable microspheres. This review discusses relevant efficacy and tolerability outcomes with exenatide once weekly in the context of its pharmacology.
METHODS: The medical literature was searched to identify relevant data on the pharmacology and clinical effects of exenatide once weekly.
FINDINGS: Exenatide once weekly, like the twice-daily formulation, has been shown to improve glycemic parameters, promote weight loss, result in beneficial changes in cardiovascular risk factors, and is well-tolerated. IMPLICATIONS: The characteristics of exenatide once weekly make it a treatment option for patients with type 2 diabetes.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  delayed-action preparations; exenatide; pharmacology; type 2 diabetes

Mesh:

Substances:

Year:  2016        PMID: 26926319     DOI: 10.1016/j.clinthera.2016.01.014

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  3 in total

1.  Association between cardiovascular health metrics and risk of incident type 2 diabetes mellitus: the Rural Chinese Cohort Study.

Authors:  Pei Qin; Dechen Liu; Yifei Feng; Xingjin Yang; Yang Li; Yuying Wu; Huifang Hu; Jinli Zhang; Tianze Li; Xi Li; Yang Zhao; Chuanqi Chen; Fulan Hu; Ming Zhang; Yu Liu; Xizhuo Sun; Dongsheng Hu
Journal:  Acta Diabetol       Date:  2022-05-28       Impact factor: 4.280

2.  Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus.

Authors:  Marie Pereira; Stephanie Gohin; Jean-Paul Roux; Amy Fisher; Mark E Cleasby; Guillaume Mabilleau; Chantal Chenu
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-20       Impact factor: 5.555

3.  Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ).

Authors:  Hitoshi Ishii; Koki Shin; Takahiro Tosaki; Tatsuya Haga; Yoshiki Nakajima; Toshihiko Shiraiwa; Nobuaki Watanabe; Miyuki Koizumi; Hiroki Nakajima; Sadanori Okada; Tsuyoshi Mashitani; Takako Mohri; Yasuhiro Akai
Journal:  Diabetes Ther       Date:  2018-03-29       Impact factor: 2.945

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.